Acumen pharmaceuticals appoints dr. james doherty as president and chief development officer

Charlottesville, va., feb. 01, 2024 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of alzheimer's disease, announced today the appointment of james doherty, ph.d., as president and chief development officer, effective february 1, 2024, reporting to daniel o'connell, chief executive officer. dr. doherty's responsibilities will include oversight of clinical and non-clinical development, chemistry, manufacturing & controls and regulatory functions.
ABOS Ratings Summary
ABOS Quant Ranking